EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells

Belinda J Petri, Kellianne M Piell, Bailey L Avila-Valdes, Christian G Stanley, Laura J Winkler, Johnny Tyler Brown, Rye Ulett, Gabriela Sanchez, Julia H Chariker, Eric C Rouchka, Carolyn M Klinge

Functional & Integrative Genomics · 2025

DOI: 10.1007/s10142-025-01658-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Functional & Integrative Genomics, 2025. Verfasst von Belinda J Petri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Methyltransferases, Adenosine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of epitranscriptomic changes in the development of acquired endocrine therapy (ET)- resistance in estrogen receptor α (ER) expressing breast cancer (BC) is unknown. We tested the hypothesis that inhibition of METTL3, the methyltransferase responsible for the mRNA modification N-6 methyladenosine (m6A), alters m6A modifications and differentially regulates the abundance of mRNA transcripts in ET-sensitive MCF-7 versus resistant LCC9 ER + human BC cells. Differential m6A modifications were identified using direct mRNA sequencing (DRS) performed on five replicates for each cell line ± 1 µM STM2457, a selective METTL3 inhibitor, using Nanopore MinION long read RNA-seq. Parallel short read Illumina RNA-seq quantified differential transcript abundance in the same samples. Selected results were validated by RT-qPCR, m6A-RIP-qPCR, reporter assays, and western blot analysis. Statistical analysis combined m6Anet, a machine-learning algorithm designed to call m6A modified bases, with a generalized linear model following a binomial distribution analysis to identify significant differential m6A modification ratios (DMR). Distinct METTL3 dependent m6A modification patterns in LCC9 and MCF-7 cells were observed in differentially expressed genes (DEG) associated with ET-resistance, including EEF1A2, ACTB, FLNA, PDIA6, AMIGO2, TPT1, XBP1, and CITED4. Select results were validated in additional ET-resistant BC cell lines. m6A-RIP-RT-qPCR validated specific m6A sites. We examined the proximity of m6A sites to estrogen receptor α (ER α)-mRNA binding sites reported in MCF-7 cells. ACTB, PDIA6, and XBP1 demonstrated a short-range proximity, with m6A sites located within 100 bp of ERα binding sites, suggesting a role for m6A in influencing ERα-mRNA binding. Our work provides a framework for integrating DRS and DEG omics data. Our results suggest a role for dysregulation of m6A modifications in pathways implicated in ET resistance in BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmMethyltransferasesAdenosineHumansFemaleMCF-7 CellsGene Expression Regulation, NeoplasticCell Line, TumorSequence Analysis, RNAEstrogen Receptor alphaRNA, Messenger

Stichwörter der Autor:innen

Breast cancerEndocrine-resistanceEpitranscriptomeM6ANanopore DRS

Substanzen

METTL3 protein, humanMethyltransferasesAdenosineN-methyladenosineEstrogen Receptor alphaRNA, MessengerESR1 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
  • Kentucky IDeA Networks of Biomedical Research Excellence Bioinformatics Core, University of Louisville School of Medicine, Louisville, KY, USA.
  • Department of Neuroscience Training, University of Louisville School of Medicine, Louisville, KY, USA.
  • Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA. carolyn.klinge@louisville.edu.
  • University of Louisville Center for Integrative Environmental Health Sciences (CIEHS), Louisville, KY, USA. carolyn.klinge@louisville.edu.

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health National Institute of General Medical Sciences
  • Office of the Assistant Secretary of Defense for Health Affairs Breast Cancer Research Program
  • Jewish Heritage Fund
  • National Institutes of Health

Zitieren

APA

Petri, B. J., Piell, K. M., Avila-Valdes, B. L., Stanley, C. G., Winkler, L. J., Brown, J. T., Ulett, R., Sanchez, G., Chariker, J. H., Rouchka, E. C., & Klinge, C. M. (2025). Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells. Functional & Integrative Genomics. https://doi.org/10.1007/s10142-025-01658-2

Vancouver

Petri BJ, Piell KM, Avila-Valdes BL, Stanley CG, Winkler LJ, Brown JT, et al. Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells. Functional & Integrative Genomics. 2025. doi:10.1007/s10142-025-01658-2

BibTeX
@article{Petri2025,
  author = {Petri, Belinda J and Piell, Kellianne M and Avila-Valdes, Bailey L and Stanley, Christian G and Winkler, Laura J and Brown, Johnny Tyler and Ulett, Rye and Sanchez, Gabriela and Chariker, Julia H and Rouchka, Eric C and Klinge, Carolyn M},
  title = {Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells},
  journal = {Functional & Integrative Genomics},
  year = {2025},
  doi = {10.1007/s10142-025-01658-2}
}
Kostenlos starten →